Shirish Gadgeel

Henry Ford Cancer Health System, MI

Dr. Gadgeel is the Chief of Division of Hematology/Oncology at Henry Ford Cancer Institute/Henry Ford Health System. He is a medical oncologist by training and his area of interest is lung cancer research in general and drug development in lung cancer, in particular. He has conducted and participated in many lung cancer specific trials and in phase I trials, including investigator initiated trials based on laboratory research. He has also been a principal investigator of a Southwest Oncology Group trial, S0528, S1507 and NCI protocol 7389. He was a co-author on major phase III trials ALEX and Keynote 189 which changed the standard of care. He has also engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African Americans and in young patients. He served as one of the PIs of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients. He served as the co-leader of the Molecular Therapeutics Program of the Core Cancer Center Grant of Karmanos Cancer Institute before joining University of Michigan. He was also the site PI for the NO1 grant awarded to the California Cancer Consortium. Subsequently, he was co-leader of the Thoracic Oncology Research Program and the Mary Lou Kennedy Research Professor in Thoracic Oncology at the University of Michigan, where he worked before joining Henry Ford Cancer Institute. His clinical research experience spans 20 years. He is a member of the steering Committee of the Lung Cancer Committee of Southwest Oncology Group (SWOG). He is a member of the Editorial Board of Clinical Lung Cancer and a reviewer for many journals including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Journal of Thoracic Oncology. He has also served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the Education Committee of ASCO. He is a member of the Communications Committee of the International Association of Study of Lung Cancer (IASLC). He was awarded by the NCI the Cancer Clinical Investigator Team Leadership Award in 2012.

Broadcast Time Zone is Eastern Standard Time (EST)
Approximately one week before the Conference, all registered delegates will receive an invitation with personal link to set their profile and enter the virtual Conference platform.  Your personal link will only be valid until the end of the Conference.  In order to view the Conference lectures and panel discussions, delegates must enter the virtual Conference platform and set their profile before the end of the Conference.